A Phase I Study of VP03 for Fibrosis
Latest Information Update: 16 Nov 2021
Price :
$35 *
At a glance
- Drugs C 106 (Primary)
- Indications Fibrosis
- Focus Adverse reactions
- Sponsors Vicore Pharma
- 04 Nov 2021 According to a Vicore Pharma media release, this trial is expected to begin in H1 2022.
- 26 Aug 2021 According to a Vicore Pharma media release, the company plans to submit a clinical trial application (CTA) for VP03 by the end of 2021.
- 08 May 2021 New trial record